Express about 16 million US dollars to help develop a new generation of CAR-T therapy, the new sharp sword refers to ovarian cancer

▎Editor of WuXi AppTec content team On October 21, 2021, Leucid Bio announced the completion of a round A financing of approximately US$16 million to launch its main research CAR-T cell therapy LEU-011 to treat platinum-based chemotherapy resistance Phase 1 clinical trial for ovarian cancer
.

The company's CAR-T therapy uses a unique chimeric antigen receptor (CAR) design, which is expected to improve the efficacy of solid tumors
.

CAR-T therapy is a revolutionary technology that recognizes and destroys cancer cells through the transformation of the patient's own immune cells
.

This has proven to be a powerful therapy for refractory blood cancers, but currently has limited effectiveness in the treatment of solid tumors
.

Leucid Bio's CAR-T cell therapy is based on a novel CAR structure
.

It is called "Parallel CAR" (pCAR).
Two CARs are expressed on the surface of CAR-T cells.
They can not only carry antibody fragments targeting different epitopes, but also carry two different costimulatory domains in the intracellular domain.

.

This design is similar to the natural arrangement of these molecules on the cell membrane
.

In preclinical studies, compared with previous generations of CAR-T therapy designs, it may better control the activation of T cells, produce sustained anti-tumor activity, and reduce cell toxic and side effects
.

Related reading: A breakthrough in cancer cell therapy! "Nature" sub-issues show new ideas, can intractable tumors be eliminated? ▲The design of parallel CAR is different from that of previous generations of CAR (picture source: Leucid Bio official website) Leucid's LEU-011 project is a CAR-T cell therapy targeting NKG2D ligand in the pre-clinical development stage.
Treatment of solid tumors and hematological malignancies
.

NKG2D receptor is an activated immune receptor that can activate T cells after recognizing the NKG2D ligand expressed on cancerous, infected or damaged cells
.

Because NKG2D ligand is expressed on more than 80% of human tumor cells, LEU-011 has the potential to treat multiple cancer types
.

Mr.
Artin Moussavi, CEO of Leucid Bio, said: “This financing will enable us to advance the LEU-011 project to the clinical development stage
.

At Leucid, we are developing improved CAR-T technology aimed at overcoming solid tumor CAR-T A key challenge in cell therapy to improve treatment outcomes and save cancer patients’ lives
.

"Reference: [1] Leucid Bio Raises £11.
5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T ) Therapies.
Retrieved October 21, 2021, from https:// Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.

This article is not a treatment recommendation either
.

If you need guidance on treatment plans, please go to a regular hospital for treatment
.